Morgan Stanley
DYN icon

Morgan Stanley’s Dyne Therapeutics DYN Stock Holding History

Morgan Stanley’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Sell
746,200
-182,803
-20% -$3.4M ﹤0.01% 3266
2026
Q1 		$16.8M Sell
929,003
-284,556
-23% -$4.91M ﹤0.01% 3115
2025
Q4 		$23.7M Sell
1,213,559
-205,448
-14% -$3.89M ﹤0.01% 2772
2025
Q3 		$18M Buy
1,419,007
+56,831
+4% +$648K ﹤0.01% 2986
2025
Q2 		$13M Sell
1,362,176
-29,411
-2% -$324K ﹤0.01% 3204
2025
Q1 		$14.6M Buy
1,391,587
+637,994
+85% +$9.13M ﹤0.01% 3004
2024
Q4 		$17.8M Sell
753,593
-299,669
-28% -$8.86M ﹤0.01% 2876
2024
Q3 		$37.8M Buy
1,053,262
+494,210
+88% +$19.7M ﹤0.01% 2125
2024
Q2 		$19.7M Sell
559,052
-403,112
-42% -$11.7M ﹤0.01% 2687
2024
Q1 		$27.3M Sell
962,164
-1,059,231
-52% -$24M ﹤0.01% 2352
2023
Q4 		$26.9M Buy
2,021,395
+1,913,653
+1,776% +$18.7M ﹤0.01% 2371
2023
Q3 		$965K Sell
107,742
-7,103
-6% -$76.5K ﹤0.01% 4823
2023
Q2 		$1.29M Buy
114,845
+1,215
+1% +$14.3K ﹤0.01% 4675
2023
Q1 		$1.31M Buy
113,630
+49,200
+76% +$639K ﹤0.01% 4707
2022
Q4 		$747K Sell
64,430
-65,110
-50% -$753K ﹤0.01% 5030
2022
Q3 		$1.65M Sell
129,540
-98,510
-43% -$1.13M ﹤0.01% 4567
2022
Q2 		$1.57M Sell
228,050
-76,493
-25% -$527K ﹤0.01% 4707
2022
Q1 		$2.94M Sell
304,543
-69,377
-19% -$591K ﹤0.01% 4217
2021
Q4 		$4.45M Buy
373,920
+270,142
+260% +$3.8M ﹤0.01% 3843
2021
Q3 		$1.69M Buy
103,778
+99,122
+2,129% +$1.76M ﹤0.01% 4706
2021
Q2 		$98K Buy
4,656
+4,530
+3,595% +$85.2K ﹤0.01% 6367
2021
Q1 		$2K Sell
126
-24,149
-99% -$467K ﹤0.01% 7262
2020
Q4 		$510K Buy
+24,275
New +$480K ﹤0.01% 5067

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley's DYN Position: Q2 2026 in Review

Morgan Stanley reduced its Dyne Therapeutics (DYN) stake by 20% in Q2 2026, selling an estimated $3.4M and leaving 746,200 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3266.

Morgan Stanley first reported a position in DYN in Q4 2020 and has held it in 23 quarters since. The position peaked at $37.8M in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Morgan Stanley held 746,200 shares of Dyne Therapeutics worth $16.6M as of Q2 2026.
  • Morgan Stanley sold 182,803 Dyne Therapeutics shares in Q2 2026, an estimated $3.4M.
  • Dyne Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3266 holding.
  • Morgan Stanley first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Dyne Therapeutics position peaked at $37.8M in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.